Soft-tissue sarcomas are rare, comprising <1% of all cancer diagnoses. Yet the diversity of histological subtypes is impressive with >100 benign and malignant soft-tissue tumor entities defined. Tissue diagnostics helps pathologists recommend treatment solutions that deliver superior patient care. Diagnosis based on examination of tissue can provide information on exact tumor type and degree of malignancy and helps to identify potential causes and consequences. The tissue diagnostics instrument, reagents and digital pathology systems are used in clinical histology, cytology, and drug discovery laboratories around the globe. Demand for excised human tissue is increasing because of the realization of personalized medicine, which relies on excised human tissue to develop innovative tests for application in patient care.
The global tissue diagnostics market segmentation is based on product type (instruments, kits), technology (digital pathology, immunohistochemistry, in-situ hybridization, special staining), end users (ambulatory surgical centers, diagnostic centers, hospitals).
The global tissue diagnostics market report provides market size (Revenue US$ Million 2014 to 2021), market share, trends and forecasts growth trends (CAGR%, 2017 to 2021). The global tissue diagnostics market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global tissue diagnostics market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.
Major players operating in the global tissue diagnostics market and profiled in this report include 3DHISTECH Ltd., Abbott Laboratories, Agilent Technologies, Becton Dickinson & Company, Cell Signaling Technologies, Danaher Corporation, GE Healthcare, Genomic Health, Inc., Roche Diagnostics (Ventana Medical Systems), and Thermo Fisher Scientific, Inc.